The role of albumin in the invasion and metastasis of hepatocellular carcinoma

Mechanism of albumin inhibiting invasion and metastasis of hepatocellular carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100052787

Enrollment

Unknown

Registered

2021-11-05

Start date

2021-11-04

Completion date

Unknown

Last updated

2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

Chronic hepatitis B group:none

Cirrhosis group:none

Liver cancer group with albumin less than 3.5g/dL:none

Liver cancer group with albumin greater than or equal to 3.5g/dL:none

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Primary liver cancer hospitalized in the Second Affiliated Hospital of Chongqing Medical University (divided into two groups: albumin =3.5g/dL); 2. Patients with hepatitis B cirrhosis; 3. Patients with chronic viral hepatitis; 4. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe immunodeficiency; 2. Patients who are unwilling to participate in the experiment.

Design outcomes

Primary

Measure	Time frame
urokinase-type plasminogen activator receptor;	—

Countries

China

Contacts

Public ContactZhang Dazhi

300595@hospital.cqmu.edu.cn+86 13452382818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026